Alvotech announced supply and commercialization agreements with Sandoz for biosimilar candidates in Canada, Australia, and New Zealand. The partnerships aim to expand patient access to biosimilars ahead of regulatory approval, with Sandoz leading regulatory filings and commercial activities in the territories. Alvotech will retain responsibility for development, global clinical activities, and manufacturing. Sandoz is committed to providing affordable biologic medicines to millions of patients in Canada, Australia, and New Zealand. The collaboration is intended to support patient access following regulatory approvals and market launches in the regions.

Read more at GlobeNewswire: Alvotech enters supply and commercialization agreements for